-
公开(公告)号：US20250114531A1
公开(公告)日：2025-04-10
申请号：US18661199
申请日：2024-05-10
Applicant: AbbVie Inc.
Inventor： Martin J. Gibler , Mark A. Bennett , Kenneth R. Waeber , Kenneth E. Hogue , Christoph L. Gillum , Patrick A. Harrell , David A. Parrott , Sean E. Mackey , Rajkumar V. Conjeevaram , Thomas Rebne , Bradley A. Clark , Jeremy L. Hemingway , Ji Zhou
Abstract: A syringe containing a high water content product and for use in a drug infusion system is provided. The syringe includes a plunger carrying front and rear o-rings made of a diene rubber compound such as chlorobutyl rubber or bromobutyl rubber to impart very low gas permeability characteristics to the o-rings. The plunger may be molded as a single part or in two parts. If molded as one part with radially-engaging mold portions, the seal glands in the plunger may include parting lines from the mold. If molded as two parts with axially-engaging mold portions, the front seal gland may include a sealing surface and under cut that has no parting line. The o-rings may be surface treated with a lubricant to improve sealing where the molding process gives rise to parting lines in the seal glands, which can result in leak paths on the ID of the o-rings. The o-rings provide a gas-tight sliding seal that can withstand temperature changes from −25° C. to 40° C. and the resulting thermal expansion and contraction of the high water content product.
-
公开(公告)号：US20200262852A1
公开(公告)日：2020-08-20
申请号：US16866400
申请日：2020-05-04
Applicant: AbbVie Inc.
Inventor： Benoit Cardinal-David , Vincent S. Chan , Kassibla E. Dempah , Brian P. Enright , Rodger F. Henry , Raimundo Ho , Ye Huang , Alexander D. Huters , Russell C. Klix , Scott W. Krabbe , Philip R. Kym , Yanbin Lao , Xiaochun Lou , Sean E. Mackey , Mark A. Matulenko , Peter T. Mayer , Christopher P. Miller , James Stambuli , Valentino J. Stella , Eric A. Voight , Zhi Wang , Geoff Zhang
IPC: C07F9/09 , A61K45/06 , A61K31/6615 , C07C47/277 , C07C309/24 , C07C281/02 , C07F9/06 , A61K31/661
Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
-
公开(公告)号：US10117843B2
公开(公告)日：2018-11-06
申请号：US15001392
申请日：2016-01-20
Applicant: AbbVie, Inc.
Inventor： Rajkumar Conjeevaram , Alexandru Deac , Ye Huang , Sean E. Mackey , Randy A. Menges , Jayne Zimmerman
Abstract: The present disclosure relates to (a) an improved pharmaceutical composition comprising a levodopa active agent and a carbidopa active agent (b) methods of producing the pharmaceutical composition and (c) methods of treating Parkinson's disease and associated conditions comprising administering the pharmaceutical composition to a subject with Parkinson's disease.
-
公开(公告)号：US11091507B2
公开(公告)日：2021-08-17
申请号：US16866400
申请日：2020-05-04
Applicant: AbbVie Inc.
Inventor： Brian P. Enright , Ye Huang , Philip R. Kym , Yanbin Lao , Xiaochun Lou , Sean E. Mackey , Peter T. Mayer , Christopher P. Miller , Valentino J. Stella , Eric A. Voight
IPC: C07F9/09 , A61K31/661 , C07F9/06 , C07C281/02 , C07C309/24 , C07C47/277 , A61K31/6615 , A61K45/06
Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
-
公开(公告)号：US20170189620A1
公开(公告)日：2017-07-06
申请号：US15462131
申请日：2017-03-17
Applicant: AbbVie Inc.
Inventor： Sean E. Mackey , Ji Zhou , Martin J. Gibler , Dennis Y. Lee
IPC: A61M5/315
CPC classification number: A61M5/31513 , A61J7/0053 , A61J15/0015 , A61J15/0061 , A61J15/0069 , A61J15/0076 , A61M5/002 , A61M5/14546 , A61M5/3135 , A61M5/31501 , A61M5/31505 , A61M2005/3101 , A61M2005/3106 , A61M2005/3131 , A61M2005/31506 , A61M2205/8206
Abstract: A syringe includes a barrel, a plunger, and a sealing member creating a seal between the plunger and the barrel. The barrel includes a first portion with a first inner diameter and a second portion with a second inner diameter that is larger than the first inner diameter. The sealing member engages the first portion of the barrel to give rise to a first contact pressure when the barrel is filled with product. The first contact pressure is sufficient to maintain a gas-tight seal over the expected temperature ranges −25° C. to 40° C. A first force is applied to the plunger to overcome the first contact pressure and move the plunger out of the first portion and into the second portion to dispense product. The sealing member engages the second portion of the barrel to give rise to a second contact pressure that is lower than the first contact pressure. A second force lower than the first force is sufficient to overcome the second contact pressure and move the plunger in the second portion to continue dispensing product. The syringe may include a restraining element for accommodating expansion of the product during freezing.
-
Patent Agency Ranking
公开(公告)号：US10174061B2
公开(公告)日：2019-01-08
申请号：US15715245
申请日：2017-09-26
Applicant: AbbVie Inc.
Inventor： Benoit Cardinal-David , Vincent S. Chan , Brian P. Enright , Ye Huang , Alexander D. Huters , Russell C. Klix , Scott W. Krabbe , Philip R. Kym , Yanbin Lao , Xiaochun Lou , Sean E. Mackey , Mark A. Matulenko , Peter T. Mayer , Christopher P. Miller , James Stambuli , Eric A. Voight , Zhi Wang , Geoff G. Zhang , Valentino J. Stella
IPC: C07F9/09 , A61K31/661 , C07F9/06 , A61K31/6615 , C07C281/02 , C07C309/24 , C07C47/277 , A61K45/06
Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
-
公开(公告)号：US20180079762A1
公开(公告)日：2018-03-22
申请号：US15715245
申请日：2017-09-26
Applicant: AbbVie Inc.
Inventor： Benoit Cardinal-David , Vincent S. Chan , Kassibla Dempah , Brian P. Enright , Rodger F. Henry , Raimundo Ho , Ye Huang , Alexander D. Huters , Russell C. Klix , Scott W. Krabbe , Philip R. Kym , Yanbin Lao , Xiaochun Lou , Sean E. Mackey , Mark A. Matulenko , Peter T. Mayer , Christopher P. Miller , James Stambuli , Eric A. Voight , Zhi Wang , Geoff G. Zhang , Valentino J. Stella
IPC: C07F9/09 , A61K31/661 , C07F9/06 , A61K45/06 , C07C47/277 , C07C309/24 , C07C281/02 , A61K31/6615
CPC classification number: C07F9/094 , A61K31/661 , A61K31/6615 , A61K45/06 , C07B2200/13 , C07C47/277 , C07C281/02 , C07C309/24 , C07F9/06 , A61K2300/00
Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
-
公开(公告)号：US09669165B2
公开(公告)日：2017-06-06
申请号：US13829251
申请日：2013-03-14
Applicant: AbbVie Inc.
Inventor： Sean E. Mackey , Ji Zhou , Martin J. Gibler , Dennis Y. Lee
CPC classification number: A61M5/31513 , A61J7/0053 , A61J15/0015 , A61J15/0061 , A61J15/0069 , A61J15/0076 , A61M5/002 , A61M5/14546 , A61M5/3135 , A61M5/31501 , A61M5/31505 , A61M2005/3101 , A61M2005/3106 , A61M2005/3131 , A61M2005/31506 , A61M2205/8206
Abstract: A syringe includes a barrel, a plunger, and a sealing member creating a seal between the plunger and the barrel. The barrel includes a first portion with a first inner diameter and a second portion with a second inner diameter that is larger than the first inner diameter. The sealing member engages the first portion of the barrel to give rise to a first contact pressure when the barrel is filled with product. The first contact pressure is sufficient to maintain a gas-tight seal over the expected temperature ranges −25° C. to 40° C. A first force is applied to the plunger to overcome the first contact pressure and move the plunger out of the first portion and into the second portion to dispense product. The sealing member engages the second portion of the barrel to give rise to a second contact pressure that is lower than the first contact pressure. A second force lower than the first force is sufficient to overcome the second contact pressure and move the plunger in the second portion to continue dispensing product. The syringe may include a restraining element for accommodating expansion of the product during freezing.
-
公开(公告)号：US09446059B2
公开(公告)日：2016-09-20
申请号：US14919418
申请日：2015-10-21
Applicant: AbbVie Inc.
Inventor： Benoit Cardinal-David , Vincent S. Chan , Kassibla E. Dempah , Brian P. Enright , Rodger F. Henry , Raimundo Ho , Ye Huang , Alexander D. Huters , Russell C. Klix , Scott W. Krabbe , Philip R. Kym , Yanbin Lao , Xiaochun Lou , Sean E. Mackey , Mark A. Matulenko , Peter T. Mayer , Christopher P. Miller , James Stambuli , Eric A. Voight , Zhi Wang , Geoff G. Zhang , Valentino J. Stella
IPC: A61K31/661 , C07F9/06 , A61K31/6615
CPC classification number: C07F9/094 , A61K31/661 , A61K31/6615 , A61K45/06 , C07B2200/13 , C07C47/277 , C07C281/02 , C07C309/24 , C07F9/06 , A61K2300/00
Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
Abstract translation: 本公开内容涉及（a）卡比多巴前药，（b）药物组合和包含卡比多巴前药和/或左旋多巴前药的组合物，和（c）治疗帕金森病和相关病症的方法，包括施用卡比多巴前药和 左旋多巴前药与帕金森病患者。
-
公开(公告)号：US20140228802A1
公开(公告)日：2014-08-14
申请号：US13829251
申请日：2013-03-14
Applicant: AbbVie Inc.
Inventor： Sean E. Mackey , Ji Zhou , Martin J. Gibler , Dennis Lee
IPC: A61M5/14
CPC classification number: A61M5/31513 , A61J7/0053 , A61J15/0015 , A61J15/0061 , A61J15/0069 , A61J15/0076 , A61M5/002 , A61M5/14546 , A61M5/3135 , A61M5/31501 , A61M5/31505 , A61M2005/3101 , A61M2005/3106 , A61M2005/3131 , A61M2005/31506 , A61M2205/8206
Abstract: A syringe includes a barrel, a plunger, and a sealing member creating a seal between the plunger and the barrel. The barrel includes a first portion with a first inner diameter and a second portion with a second inner diameter that is larger than the first inner diameter. The sealing member engages the first portion of the barrel to give rise to a first contact pressure when the barrel is filled with product. The first contact pressure is sufficient to maintain a gas-tight seal over the expected temperature ranges −25° C. to 40° C. A first force is applied to the plunger to overcome the first contact pressure and move the plunger out of the first portion and into the second portion to dispense product. The sealing member engages the second portion of the barrel to give rise to a second contact pressure that is lower than the first contact pressure. A second force lower than the first force is sufficient to overcome the second contact pressure and move the plunger in the second portion to continue dispensing product. The syringe may include a restraining element for accommodating expansion of the product during freezing.
Abstract translation: 注射器包括筒，柱塞和在柱塞和筒之间形成密封的密封构件。 枪管包括具有第一内径的第一部分和具有大于第一内径的第二内径的第二部分。 密封构件与筒体的第一部分接合以在桶体填充产品时产生第一接触压力。 第一接触压力足以在-25℃至40℃的预期温度范围内保持气密密封。将第一力施加到柱塞以克服第一接触压力并将柱塞移出第一接触压力 部分并进入第二部分以分发产品。 密封构件与筒的第二部分接合以产生低于第一接触压力的第二接触压力。 低于第一力的第二力足以克服第二接触压力并且使第二部分中的柱塞移动以继续分配产物。 注射器可以包括用于在冷冻期间容纳产品的膨胀的约束元件。
-
-
-
-
-
-
-
-
-
Search Results
13
records
(took 0.019 seconds)
